{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:12:40Z","timestamp":1789985560136,"version":"4.0.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2017-0046_s_999_w2aab3b7c11b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic syndrome (MetS) involves a cluster of cardiovascular risk factors, including abnormal lipids, insulin resistance and hypertension. The aim of the present study is to investigate associations between thyroid profile and the pro-thrombotic mediator, plasminogen activator inhibitor-1 (PAI-1), in MetS and identify associated biochemical markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2017-0046_s_998_w2aab3b7c11b1b6b1aab1c14b2Aa\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The present study was a case control study and consisted of 50 diagnosed cases of MetS and 50 healthy volunteers as controls. MetS cases were further divided into two groups based on the presence and absence of subclinical hypothyroidism (SCH). Data collected included demographic profile, clinical history and routine lab investigation. Special investigations included the thyroid function test and serum PAI-1 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2017-0046_s_997_w2aab3b7c11b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean serum thyroid-stimulating hormone (TSH) levels were significantly higher in MetS cases as compared to controls (5.7\u2009\u00b1\u20091.2 mIU\/L vs. 2.3\u2009\u00b1\u20091.6 mIU\/L, p\u2009&lt;\u20090.0001), although the mean triiodothyronine (T\n                      <jats:sub>3<\/jats:sub>\n                      ) and\u00a0thyroxine (T\n                      <jats:sub>4<\/jats:sub>\n                      ) levels were comparable in two groups. The mean levels of serum PAI-1 were significantly higher in MetS cases as compared to controls(231\u2009\u00b1\u200987 ng\/mL vs. 185\u2009\u00b1\u200996 ng\/mL, p\u2009=\u20090.013). TSH and PAI-1 levels were positively correlated with various markers of MetS and negatively correlated with high-density lipoprotein (HDL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2017-0046_s_996_w2aab3b7c11b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study points towards the presence of thyroid dysfunction, in the form of subclinical hypothyroidism (SCH), in cases of MetS. In the presence of thyroid dysfunction, abnormal adipocytes may release adipokines, such as PAI-1, which lead to increased risk of thrombotic episodes in these patients. Hence, SCH should be appropriately managed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2017-0046","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T17:16:52Z","timestamp":1513790212000},"source":"Crossref","is-referenced-by-count":4,"title":["Association of prothrombotic adipokine (plasminogen activator inhibitor-1) with TSH in metabolic syndrome: a case control study"],"prefix":"10.1515","volume":"34","author":[{"given":"Ashok Kumar","family":"Ahirwar","sequence":"first","affiliation":[{"name":"Department of Biochemistry , All India Institute of Medical Sciences (AIIMS) , Room no. 3013, Third Floor, Teaching Block, AIIMS, Ansari Nagar , New Delhi-110029 , India , Phone: +919654210832"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , All India Institute of Medical Sciences (AIIMS) , New Delhi-110029 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Lady Hardinge Medical College (LHMC) , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Kaim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology , Deen Dayal Upadhyay Hospital , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Rajiv Gandhi Super Speciality Hospital , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajeet Kumar","family":"Patra","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Lady Hardinge Medical College (LHMC) , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Maulana Azad Medical College , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Lady Hardinge Medical College (LHMC) , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Department of Biochemistry , Lady Hardinge Medical College (LHMC) , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"2025121207393601483_j_hmbci-2017-0046_ref_001_w2aab3b7c11b1b6b1ab2b2b1Aa","unstructured":"Longo DL, Fauci AS, Kasper DL. principles of internal medicine,Harrison\u2019sHarrison\u2019s principles of internal medicine,18th edn. New York, NY:  McGraw-Hill, 2012."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_002_w2aab3b7c11b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Eapen D, Kalra GL, Merchant N, Arora A, Khan BV. Metabolic syndrome and cardiovascular disease in South Asians. Vasc Health Risk Manag. 2009;5:731.","DOI":"10.2147\/VHRM.S5172"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_003_w2aab3b7c11b1b6b1ab2b2b3Aa","unstructured":"Kaur P, Radhakrishnan E, Rao SR, Sankarasubbaiyan S, Roa TV, Gupte MD. The metabolic syndrome and associated risk factors in an urban industrial male population in South India. J Assoc Physicians India. 2010;58:363."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_004_w2aab3b7c11b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol. 2009;29:311\u20135.","DOI":"10.1161\/ATVBAHA.109.184085"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_005_w2aab3b7c11b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Squizzato A, Romualdi E, Piantanida E, Gerdes VE, B\u00fcller HR, Tanda M, et al. Subclinical hypothyroidism and deep venous thrombosis-A pilot cross-sectional study. Thromb Haemost. 2007;97:803\u20136.","DOI":"10.1160\/TH06-12-0682"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_006_w2aab3b7c11b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Gohill BC, Rosenblum LA, Coplan JD, Kral JG. Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. CNS Spectr. 2001;6:581\u20136.","DOI":"10.1017\/S1092852900002121"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_007_w2aab3b7c11b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and Atherogenesis. J. Endocrinol. 2003;144:2195\u2013200.","DOI":"10.1210\/en.2003-0285"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_008_w2aab3b7c11b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Pinkney JH, Goodrick SJ, Katz J, Johnson AB, Lightman SL, Coppack SW, et al. Leptin and the pituitary-thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf). 1998;49:583\u20138.","DOI":"10.1046\/j.1365-2265.1998.00573.x"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_009_w2aab3b7c11b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Chugh K, Goyal S, Shankar V, Chugh SN. Thyroid function tests in metabolic syndrome. Indian J Endocr Metab. 2012;16:958\u201361.","DOI":"10.4103\/2230-8210.102999"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_010_w2aab3b7c11b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Vito PD, Candelotti E, Ahmed RG, Luly P, Davis PJ, Incerpi S, et al. Role of thyroid hormones in insulin resistance and diabetes. Immun Endocr Metab Agents Med Chem. 2015;15:86\u201393.","DOI":"10.2174\/187152221501150710132153"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_011_w2aab3b7c11b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol. 2010;162:439\u201351.","DOI":"10.1530\/EJE-09-0958"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_012_w2aab3b7c11b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001;86:732\u20137.","DOI":"10.1210\/jcem.86.2.7221"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_013_w2aab3b7c11b1b6b1ab2b2c13Aa","unstructured":"Burtis CA, Ashwood ER, Bruns ED. Tietz textbook of clinical chemistry and molecular diagnostic. Philadelphia, PA, USA: Saunders Elsevier; 2008. 2170 p."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_014_w2aab3b7c11b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Liu YY, Schultz JJ, Brent GA. A thyroid hormone receptor alpha gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice. J Biol Chem. 2003;278:38913\u201320.","DOI":"10.1074\/jbc.M306120200"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_015_w2aab3b7c11b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Santini F, Marzullo P, Rotondi M, Ceccarini G, Pagano L, Ippolito S, et al. Mechanisms in endocrinology: the crosstalk between thyroid gland and adipose tissue: signal integration in health and disease. Eur J Endocrinol. 2014;171:R137\u201352.","DOI":"10.1530\/EJE-14-0067"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_016_w2aab3b7c11b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Gyawali P, Takanche JS, Shrestha RK, Bhattarai P, Khanal K, Risal P, et al. Pattern of thyroid dysfunction in patients with metabolic syndrome and its relationship with components of metabolic syndrome. Diabetes Metab J. 2015;39:66\u201373.","DOI":"10.4093\/dmj.2015.39.1.66"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_017_w2aab3b7c11b1b6b1ab2b2c17Aa","unstructured":"Levesque H, Borg JY, Cailleux N, Vasse M, Daliphard S, Gancel A, et al. Acquired von Willebrand\u2019s syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J Med. 1993;2:287\u20138."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_018_w2aab3b7c11b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr Pract. 2009;15:254\u201362.","DOI":"10.4158\/EP.15.3.254"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_019_w2aab3b7c11b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Ogbera AO, Kuku S, Dada O. The metabolic syndrome in thyroid disease: a report from Nigeria. Indian J Endocrinol Metab. 2012;16:417\u201322.","DOI":"10.4103\/2230-8210.95688"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_020_w2aab3b7c11b1b6b1ab2b2c20Aa","unstructured":"Bilgili S, Celebiler AC, Dogan A, Karaca B. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul. 2008;42:63\u20138."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_021_w2aab3b7c11b1b6b1ab2b2c21Aa","unstructured":"Kapadia KB, Bhatt PA, Shah JS. Association between altered thyroid state and insulin resistance. J Pharmacol Pharmacother. 2012;3:156."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_022_w2aab3b7c11b1b6b1ab2b2c22Aa","unstructured":"Deeg M, Baiyewu O, Gao S, Ogunniyi A, Shen J, Gureje O, et al. A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians. Ethn Dis. 2008;1:427."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_023_w2aab3b7c11b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115:151\u201362.","DOI":"10.1016\/S0092-8674(03)00771-2"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_024_w2aab3b7c11b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, et al. Recombinant human TSH modulates in vivo C\u2010telopeptides of type\u20101 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res. 2005;20:480\u20136.","DOI":"10.1359\/JBMR.041126"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_025_w2aab3b7c11b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr 2000;71:1421\u201332.","DOI":"10.1093\/ajcn\/71.6.1421"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_026_w2aab3b7c11b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Horm Metab Res. 2000;32:468\u201374.","DOI":"10.1055\/s-2007-978672"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_027_w2aab3b7c11b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptorgamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352\u20138.","DOI":"10.1210\/jcem.87.5.8472"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_028_w2aab3b7c11b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Bastemir M, Akin F, Alkis E, Kaptanoglu B. Obesity is associated with increased serum TSH level, independent of thyroid function. Swiss Med Wkly. 2007;137:431.","DOI":"10.4414\/smw.2007.11774"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_029_w2aab3b7c11b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Salloum-Asfar S, Boelen A, Reitsma PH, van Vlijmen BJ. The immediate and late effects of thyroid hormone (triiodothyronine) on murine coagulation gene transcription. PloS one. 2015;10:e0127469.","DOI":"10.1371\/journal.pone.0127469"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_030_w2aab3b7c11b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Debeij J, Cannegieter SC, van Zaane B, Smit JW, Corssmit EP, Rosendaal FR, et al. The effect of changes in thyroxine and thyroid\u2010stimulating hormone levels on the coagulation system. J Thromb Haemost. 2010;8:2823\u20136.","DOI":"10.1111\/j.1538-7836.2010.04054.x"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_031_w2aab3b7c11b1b6b1ab2b2c31Aa","unstructured":"Kovarova M, Koller T, Stvrtinova V, Payer J. Thyroid-stimulating hormone concentration as an independent risk factor of venous thromboembolism regardless of thyroid function. Endokrynologia Polska. 2015;66:474\u20139."},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_032_w2aab3b7c11b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Serter R, Demirbas B, Korukluoglu B, Culha C, Cakal E, Aral Y. The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism. Invest J Endocrinol. 2004;27:897\u2013903.","DOI":"10.1007\/BF03347530"},{"key":"2025121207393601483_j_hmbci-2017-0046_ref_033_w2aab3b7c11b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Phelan M, Kerins DM. The role of plasminogen activator inhibitor-1 in the metabolic syndrome and its regulation. J Food Res. 2014;3:36.","DOI":"10.5539\/jfr.v3n6p36"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.ahead-of-print\/hmbci-2017-0046\/hmbci-2017-0046.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2017-0046\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2017-0046\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:14:34Z","timestamp":1765530874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2017-0046\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,15]]},"published-print":{"date-parts":[[2018,4,25]]}},"alternative-id":["10.1515\/hmbci-2017-0046"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2017-0046","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,20]]},"article-number":"20170046"}}